{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-020081","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.222623+00:00","generated_at":"2026-05-19T14:02:46.653568+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Allarity Therapeutics appoints Jesper Høiland to board, replacing Joseph Vazzano","bullets":["Joseph Vazzano resigned as director effective June 30, 2025.","Jesper Høiland appointed director effective June 30, 2025; term expires at 2026 annual meeting.","Høiland joins Audit, Compensation, and Nominating & Governance Committees.","Høiland receives $50,000 annual retainer plus committee fees ($7,500/$5,000/$4,000).","Høiland had served as strategic consultant since Oct 2024; background includes Novo Nordisk and Radius Health."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-020081","json":"https://secwatch.observer/filing/0001437749-25-020081.json","markdown":"https://secwatch.observer/filing/0001437749-25-020081.md","text":"https://secwatch.observer/filing/0001437749-25-020081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020081/0001437749-25-020081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020081/allr20250611_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T14:02:46.653568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b04592fe3a","claim":"Jesper Høiland was appointed as director at Allarity Therapeutics, Inc..","evidence_excerpt":"On June 10, 2025, the Board appointed Mr. Jesper Høiland as a director of the Company, effective as of June 30, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020081/0001437749-25-020081-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"fe9c8c7e24","claim":"Joseph W. Vazzano resigned as director at Allarity Therapeutics, Inc..","evidence_excerpt":"On June 5, 2025, the Board of Directors (the “ Board ”) of Allarity Therapeutics, Inc. (the “ Company ”) received the resignation of Joseph W. Vazzano as director of the Company, effective June 30, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020081/0001437749-25-020081-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}